USA - NYSE:IQV - US46266C1053 - Common Stock
The current stock price of IQV is 220.52 USD. In the past month the price increased by 22.81%. In the past year, price increased by 2.74%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.56 | 216.18B | ||
| DHR | DANAHER CORP | 28.92 | 159.69B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 148.65 | 48.49B | ||
| A | AGILENT TECHNOLOGIES INC | 27.16 | 41.97B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.07 | 29.55B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 42.07 | 21.39B | ||
| WAT | WATERS CORP | 29.39 | 21.40B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.32 | 17.00B | ||
| ILMN | ILLUMINA INC | 24.06 | 15.39B | ||
| TEM | TEMPUS AI INC | N/A | 15.50B | ||
| ICLR | ICON PLC | 13.5 | 13.85B | ||
| RVTY | REVVITY INC | 20.22 | 11.48B |
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. The company is headquartered in Durham, North Carolina and currently employs 90,000 full-time employees. The company went IPO on 2013-05-09. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
IQVIA HOLDINGS INC
2400 Ellis Road
Durham NORTH CAROLINA 27703 US
CEO: Ari Bousbib
Employees: 90000
Phone: 19199982000
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. The company is headquartered in Durham, North Carolina and currently employs 90,000 full-time employees. The company went IPO on 2013-05-09. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
The current stock price of IQV is 220.52 USD. The price increased by 0.28% in the last trading session.
IQV does not pay a dividend.
IQV has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IQV.
IQVIA HOLDINGS INC (IQV) currently has 90000 employees.
ChartMill assigns a technical rating of 8 / 10 to IQV. When comparing the yearly performance of all stocks, IQV turns out to be only a medium performer in the overall market: it outperformed 58.25% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to IQV. IQV has an excellent profitability rating, but there are concerns on its financial health.
Over the last trailing twelve months IQV reported a non-GAAP Earnings per Share(EPS) of 11.47. The EPS increased by 9.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 7.88% | ||
| ROA | 4.32% | ||
| ROE | 21.41% | ||
| Debt/Equity | 2.45 |
29 analysts have analysed IQV and the average price target is 220.67 USD. This implies a price increase of 0.07% is expected in the next year compared to the current price of 220.52.
For the next year, analysts expect an EPS growth of 7.56% and a revenue growth 5.12% for IQV